6-(Difluoromethyl)-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid | 215122-86-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 6-(Difluoromethyl)-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid
• 英文别名: 6-(difluoromethyl)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid
• CAS: 215122-86-4
• 化学式: C₁₂H₇F₅O₃
• 分子量: 294.178
• InChiKey: RFAPYHAMDZJRPR-UHFFFAOYSA-N

物化性质

• 沸点：
  346.3±42.0 °C(Predicted)
• 密度：
  1.533±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  ethyl 2,6-bis(trifluoromethyl)-4-oxo-4H-1-benzopyran-3-carboxylate 在 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 以60%的产率得到6-(Difluoromethyl)-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid
  参考文献：
  名称：

  Substituted benzopyran analogs for the treatment of inflammation

  摘要：

  描述了一类苯并吡喃、苯并硫吡喃、二氢喹啉、二氢萘和其类似物，用于治疗环氧化酶-2介导的疾病。特别感兴趣的化合物由Formula I'定义，其中X、A.sup.1、A.sup.2、A.sup.3、A.sup.4、R、R"、R.sup.1和R.sup.2如规范中所述。

  公开号：

  US06077850A1

文献信息

• Substituted benzopyran analogs for the treatment of inflammation
  申请人：G.D. Searle & Co.

  公开号：US06077850A1

  公开（公告）日：2000-06-20

  A class of benzopyrans, benzothiopyrans, dihydroquinolines, dihydronaphthalenes, and analogs thereof, is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I'wherein X, A.sup.1, A.sup.2, A.sup.3, A.sup.4, R, R", R.sup.1 and R.sup.2 are as described in the specification.

  描述了一类苯并吡喃、苯并硫吡喃、二氢喹啉、二氢萘和其类似物，用于治疗环氧化酶-2介导的疾病。特别感兴趣的化合物由Formula I'定义，其中X、A.sup.1、A.sup.2、A.sup.3、A.sup.4、R、R"、R.sup.1和R.sup.2如规范中所述。
• Substituted benzopyran derivatives for the treatment of inflammation
  申请人：G.D. Searle & Co.

  公开号：US06034256A1

  公开（公告）日：2000-03-07

  A class of benzopyran, derivatives is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I' ##STR1## wherein X, A.sup.1, A.sup.2, A.sup.3, A.sup.4, R, R", R.sup.1 and R.sup.2 are as described in the specification.

  所描述的苯并吡喃类衍生物用于治疗环氧合酶-2介导的疾病。特别感兴趣的化合物由式I'定义，其中X、A.sup.1、A.sup.2、A.sup.3、A.sup.4、R、R"、R.sup.1和R.sup.2如规范中描述。
• Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
  申请人：Pulaski P. Steven

  公开号：US20050014729A1

  公开（公告）日：2005-01-20

  A method for preventing or treating dermatological disorders and dermatological disorder-related complications in a subject involves a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and a dermatological treatment agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and a dermatological treatment agent. Pharmaceutical compositions and kits for implementing the present method are also described.

  一种预防或治疗受试者的皮肤病和与皮肤病相关并发症的方法涉及使用Cox-2抑制剂进行单独治疗或与Cox-2抑制剂和皮肤治疗剂的联合治疗。还描述了包含Cox-2抑制剂和皮肤治疗剂的治疗组合物。还描述了用于实施本方法的药物组合物和工具包。
• [EN] METHOD FOR PREVENTING OR TREATING AN OPTIC NEUROPATHY<br/>[FR] METHODE PERMETTANT DE PREVENIR OU DE TRAITER UNE NEUROPATHIE OPTIQUE
  申请人：PHARMACIA CORP

  公开号：WO2005021004A1

  公开（公告）日：2005-03-10

  The present invention provides methods and compositions for the prevention and/or treatment of an optic neuropathy, comprising a Cox-2 inhibitor and an intraocular pressure reducing agent.

  本发明提供了一种预防和/或治疗视神经病变的方法和组合物，包括Cox-2抑制剂和降低眼压的药剂。
• Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
  申请人：Pharmacia Corporation

  公开号：US20040204471A1

  公开（公告）日：2004-10-14

  A method for preventing or treating otic disorders and otic disorder-related complications in a subject involves a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and an otic agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and an otic agent. Pharmaceutical compositions and kits for implementing the present method are also described.

  一种用于预防或治疗主体的耳部疾病和耳部疾病相关并发症的方法涉及使用Cox-2抑制剂进行单一疗法或使用Cox-2抑制剂和耳部药剂进行联合疗法。还描述了包含Cox-2抑制剂和耳部药剂的治疗组合物。还描述了用于实施本方法的药物组合物和工具包。